晚期前列腺癌:AUA/SUO指南修正案(2026)第一部分:生化复发(局部治疗耗尽后)与转移性激素敏感性前列腺癌的评估与治疗
美国泌尿外科协会(AUA)在2025年更新文献回顾(ULR)后,通过修正案流程纳入2023年版指南发布以来的新证据。本文为两部分系列的第一部分,针对生化复发(BCR)和转移性激素敏感性前列腺癌(mHSPC)的评估与管理提供更新推荐。
要点
- 指南修正案基于2022年3月16日至2025年8月26日发表的38项研究更新证据。
- 第一部分涵盖影像学、胚系与体细胞检测、局部治疗耗尽后BCR及mHSPC的评估与治疗。
- 随着诊断与治疗选择不断演变,该指南将需要进一步审查。
核心结论
- 本修正案第一部分提供了关于影像学、胚系与体细胞检测、局部治疗耗尽后BCR及mHSPC评估与治疗的更新指导。
研究设计与样本
- 通过AUA更新文献回顾(ULR)流程审查AUA/SUO晚期前列腺癌指南,识别出2022年3月16日至2025年8月26日发表的38项研究进行全文审查。
主要发现
- 专家组基于更新审查制定了循证和共识声明,以指导晚期前列腺癌的评估与管理。
临床怎么用
- 临床可依据本修正案第一部分更新对BCR(局部治疗耗尽后)和mHSPC患者的影像学、胚系与体细胞检测及治疗决策。
局限性
- 指南声明需随着该领域诊断与治疗选择的持续演变而进一步审查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Following completion of the 2025 Update Literature Review (ULR), the American Urological Association (AUA) incorporated new evidence generated since the 2023 publication of this Guideline via the AUA Amendment process. The summary presented herein represents Part I of the two-part series dedicated to addressing updated recommendations to provide a clinical framework for the evaluation and management of biochemically recurrent (BCR) and metastatic hormone-sensitive prostate cancer (mHSPC). MATERIALS AND METHODS: The AUA/SUO Advanced Prostate Cancer Guideline was reviewed via the AUA ULR process, which identified 38 studies for full-text review that were published between March 16, 2022 and August 26, 2025. Relevant studies were incorporated into the Guideline evidence base, and Guideline statements were updated as appropriate. RESULTS: The Panel developed evidence- and consensus-based statements based on an updated review to provide guidance on evaluation and management of advanced prostate cancer. These updates are detailed herein. CONCLUSIONS: Part I of this Amendment provides updated guidance on imaging, germline and somatic testing, and evaluation and treatment of BCR following exhaustion of local therapy and mHSPC. This Guideline will require further review as the diagnostic and treatment options in this space continue to evolve.
引用
- Scarpato KR, Cookson MS, Dreicer R, et al. Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part I: Evaluation and Treatment of Biochemically Recurrent (Following Exhaustion of Local Therapy) and Metastatic Hormone-Sensitive Prostate Cancer. J Urol. 2026. PMID: 42462144. doi:10.1097/JU.0000000000005220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。